Toro-Gutierrez Juan Sebastian, Espejo-Herrero Juan Jose, Lombardo-Galera Maria Sagrario, Pérez-Montilla Maria Eugenia, Canis-López Miguel, Zurera-Tendero Luis, Rubio Juan Manuel
Unidad de Radiología Vascular e Intervencionista.Hospital Universitario Reina Sofía. Córdoba. España.
Hospital de la Cruz Roja. Córdoba. España.
Arch Esp Urol. 2017 Jun;70(5):525-533.
To analyze retrospectively the safety and effectiveness of percutaneous microwave ablation of solid renal tumors, and also review different approach techniques.
It is a retrospective study approved by the ethics committee of both hospitals. 14 tumors with a mean size of 37 mm (12-50 mm) were treated in a single session, under general anesthesia and with CT guidance, in 14 patients (9 men) with a mean age of 66 years, using the ablation system AMICA by different approaches (trans pulmonary, trans peritoneal and retroperitoneal). A biopsy was performed with a core needle to 13 of them prior to ablation in the same session. CT abdominal follow-up was performed (with and without i.v. contrast) at 1, 3, 6, 12, 18 and 24 months after ablation. Changes in serum creatinine levels pre- and post-ablation were also analyzed.
The average follow-up time was 16.5 months (3-28 months) and we obtained complete response in 100% of the treated tumors. Only two minor complications were observed: one self-limited perirenal hemorrhage and one asymptomatic hydronephrosis, in the two patients to whom we did a transpulmonary approach, without pneumothorax in any of them.
Percutaneous ablation of renal tumors seems to be a safe and effective technique, either via transpulmonary, transperitoneal or retroperitoneal approach, depending on tumor location.
• Microwave ablation produces coagulation necrosis. • The sink effect is smaller in microwave ablation. • Microwave ablation seems to be safe and effective. • The type of approach is not correlated with major complications (Clavien > o =II).
回顾性分析经皮微波消融实性肾肿瘤的安全性和有效性,并探讨不同的入路技术。
本研究为回顾性研究,经两家医院伦理委员会批准。14例患者(9例男性)平均年龄66岁,在全身麻醉和CT引导下,使用AMICA消融系统,通过不同入路(经肺、经腹和经腹膜后)单次治疗14个平均大小为37mm(12 - 50mm)的肿瘤。其中13个肿瘤在消融术前同期进行了粗针活检。消融术后1、3、6、12、18和24个月进行腹部CT随访(静脉注射对比剂和未注射对比剂)。还分析了消融前后血清肌酐水平的变化。
平均随访时间为16.5个月(3 - 28个月),所有治疗的肿瘤均获得完全缓解。仅观察到2例轻微并发症:1例自限性肾周出血和1例无症状肾积水,均发生在经肺入路的2例患者中,均未发生气胸。
经皮消融肾肿瘤似乎是一种安全有效的技术,根据肿瘤位置可采用经肺、经腹或经腹膜后入路。
• 微波消融产生凝固性坏死。• 微波消融中的热沉效应较小。• 微波消融似乎安全有效。• 入路类型与严重并发症(Clavien>o =II)无关。